The SENSCIS® study, co-led by Cleveland Clinic’s Kristin Highland, MD, explores the use of nintedanib in patients with scleroderma-associated interstitial lung disease.
Approved vasodilation therapies generally don’t improve function in patients with pulmonary hypertension associated with connective tissue disease. The Catalyst study explores the use of bardoxolone in these patients.
The TRAIL-1 study explores the use of pirfenidone, an antifibrotic agent approved for idiopathic pulmonary fibrosis, in patients with rheumatoid arthritis-associated interstitial lung disease.
IPF is still underappreciated by pulmonologists and primary care physicians. This article attempts to close that information gap by offering an overview of available treatment modalities.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Our multidisciplinary team treats local and national patients with this chronic and progressive lung disease.
Several aspects of this case deviate from the classic SLE presentation, but uncommon cases are common in Cleveland Clinic’s Lupus Clinic.
In this unusual case, a referring pathologist suspects adenocarcinoma; Dr. Mukhopadhyay explains why another diagnosis is a better fit.
The clinical phenotype of melanoma differentiation associated protein 5 (MDA-5) dermatomyositis represents an overlap of a severe form of vasculopathy and rapidly progressive ILD.
Cleveland Clinic is part of the largest scleroderma trial ever undertaken to evaluate the efficacy and safety of oral nintedanib treatment in systemic sclerosis associated interstitial lung disease.
Decisions about complex rheumatic conditions often must be based on expert opinions alone if RCTs aren’t available, especially when pulmonary disease is involved. Here’s how a combined rheumatology-pulmonary clinic can help.